Clinical application of molecular pathology in sarcomas

被引:9
作者
Romeo, Salvatore [1 ]
Tos, Angelo P. Dei [1 ]
机构
[1] Gen Hosp Treviso, Dept Pathol, I-31100 Treviso, Italy
关键词
molecular pathology; oncology; sarcoma; tailored treatment; translocation; GASTROINTESTINAL STROMAL TUMORS; SOFT-TISSUE SARCOMAS; SSX FUSION TYPE; SYNOVIAL SARCOMA; PHASE-II; IMATINIB; DOCETAXEL; CANCER; GEMCITABINE; THERAPY;
D O I
10.1097/CCO.0b013e328347b9be
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review This review is intended to highlight the clinical application of molecular pathology as a tool for diagnostic accuracy and prognostic and predictive use and finally to discover novel molecular therapeutic targets. Recent findings We are living an exciting era in sarcomas' therapy. This is the result of overcoming two crucial obstacles: lack of effective and specific drugs; lack of specific therapeutic regimen for distinct clinical entities. As new specific drugs have become available, it has become clear that an accurate diagnosis is the prerequisite for a specific therapy. This approach has been successfully applied to gastrointestinal stromal tumor and is now also being used in other sarcomas. The more recent findings are hereby reviewed. Summary The inclusion of the molecular pathology in the diagnostic surgical pathology is instrumental for the application of molecularly tailored therapy. However, the degree of complexity of this approach requires additional caution in the data interpretation and in the reproducibility of the results. As molecular knowledge is improving and more sophisticated and powerful techniques are going to be routinely used, the success rate in treating sarcomas is expected to significantly increase.
引用
收藏
页码:379 / 384
页数:6
相关论文
共 45 条
[1]   KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors [J].
Antonescu, Cristina R. ;
Yoshida, Akihiko ;
Guo, Tianhuo ;
Chang, Ning-En ;
Zhang, Lei ;
Agaram, Narasimhan P. ;
Qin, Li-Xuan ;
Brennan, Murray F. ;
Singer, Samuel ;
Maki, Robert G. .
CANCER RESEARCH, 2009, 69 (18) :7175-7179
[2]   Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy [J].
Barretina, Jordi ;
Taylor, Barry S. ;
Banerji, Shantanu ;
Ramos, Alexis H. ;
Lagos-Quintana, Mariana ;
DeCarolis, Penelope L. ;
Shah, Kinjal ;
Socci, Nicholas D. ;
Weir, Barbara A. ;
Ho, Alan ;
Chiang, Derek Y. ;
Reva, Boris ;
Mermel, Craig H. ;
Getz, Gad ;
Antipin, Yevgenyi ;
Beroukhim, Rameen ;
Major, John E. ;
Hatton, Charles ;
Nicoletti, Richard ;
Hanna, Megan ;
Sharpe, Ted ;
Fennell, Tim J. ;
Cibulskis, Kristian ;
Onofrio, Robert C. ;
Saito, Tsuyoshi ;
Shukla, Neerav ;
Lau, Christopher ;
Nelander, Sven ;
Silver, Serena J. ;
Sougnez, Carrie ;
Viale, Agnes ;
Winckler, Wendy ;
Maki, Robert G. ;
Garraway, Levi A. ;
Lash, Alex ;
Greulich, Heidi ;
Root, David E. ;
Sellers, William R. ;
Schwartz, Gary K. ;
Antonescu, Cristina R. ;
Lander, Eric S. ;
Varmus, Harold E. ;
Ladanyi, Marc ;
Sander, Chris ;
Meyerson, Matthew ;
Singer, Samuel .
NATURE GENETICS, 2010, 42 (08) :715-U103
[3]   Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor [J].
Bauer, Sebastian ;
Yu, Lynn K. ;
Demetri, George D. ;
Fletcher, Jonathan A. .
CANCER RESEARCH, 2006, 66 (18) :9153-9161
[4]   Current perspectives on HER2 testing:: A review of national testing guidelines [J].
Bilous, M ;
Dowsett, M ;
Hanna, W ;
Isola, J ;
Lebeau, A ;
Moreno, A ;
Penault-Llorca, F ;
Rüschoff, J ;
Tomasic, G ;
de Vijver, MV .
MODERN PATHOLOGY, 2003, 16 (02) :173-182
[5]   MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes -: A comparative analysis of 559 soft tissue neoplasms with genetic data [J].
Binh, MBN ;
Sastre-Garau, X ;
Guillou, L ;
de Pinieux, G ;
Terrier, P ;
Lagacé, R ;
Aurias, A ;
Hostein, I ;
Coindre, JM .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (10) :1340-1347
[6]   Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Casali, P. G. ;
Blay, J. -Y. .
ANNALS OF ONCOLOGY, 2010, 21 :v98-v102
[7]   Do rare cancers deserve specific strategies for cancer research? [J].
Casali, Paolo G. .
LANCET ONCOLOGY, 2010, 11 (06) :506-507
[8]   Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity [J].
Chibon, Frederic ;
Lagarde, Pauline ;
Salas, Sebastien ;
Perot, Gaelle ;
Brouste, Veronique ;
Tirode, Franck ;
Lucchesi, Carlo ;
de Reynies, Aurelien ;
Kauffmann, Audrey ;
Bui, Binh ;
Terrier, Philippe ;
Bonvalot, Sylvie ;
Le Cesne, Axel ;
Vince-Ranchere, Dominique ;
Blay, Jean-Yves ;
Collin, Francoise ;
Guillou, Louis ;
Leroux, Agnes ;
Coindre, Jean-Michel ;
Aurias, Alain .
NATURE MEDICINE, 2010, 16 (07) :781-U81
[9]   Prognostic factors in adult patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group [J].
Coindre, JM ;
Terrier, P ;
Bui, NB ;
Bonichon, F ;
Collin, F ;
LeDoussal, V ;
Mandard, AM ;
Vilain, MO ;
Jacquemier, J ;
Duplay, H ;
Sastre, X ;
Barlier, C ;
HenryAmar, M ;
Lesech, JM ;
Contesso, G .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :869-877
[10]   Drug Insight: vascular disrupting agents and angiogenesis - novel approaches for drug delivery [J].
Cooney, Matthew M. ;
van Heeckeren, Willem ;
Bhakta, Shyam ;
Ortiz, Jose ;
Remick, Scot C. .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (12) :682-692